Revolution Medicines, Inc. $RVMD Shares Sold by Tema Etfs LLC

Tema Etfs LLC trimmed its position in Revolution Medicines, Inc. (NASDAQ:RVMD) by 20.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,603 shares of the company’s stock after selling 26,318 shares during the period. Tema Etfs LLC’s holdings in Revolution Medicines were worth $8,013,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of RVMD. GAMMA Investing LLC raised its position in Revolution Medicines by 45.1% during the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after buying an additional 260 shares during the last quarter. Danske Bank A S acquired a new position in shares of Revolution Medicines during the third quarter worth about $98,000. FNY Investment Advisers LLC acquired a new position in shares of Revolution Medicines during the third quarter worth about $110,000. Osaic Holdings Inc. raised its holdings in Revolution Medicines by 41.7% during the second quarter. Osaic Holdings Inc. now owns 3,487 shares of the company’s stock worth $128,000 after purchasing an additional 1,027 shares in the last quarter. Finally, US Bancorp DE raised its holdings in Revolution Medicines by 170.3% during the third quarter. US Bancorp DE now owns 3,168 shares of the company’s stock worth $148,000 after purchasing an additional 1,996 shares in the last quarter. 94.34% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on RVMD shares. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a report on Friday, January 9th. UBS Group initiated coverage on Revolution Medicines in a research note on Friday, February 27th. They set a “buy” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Truist Financial upgraded Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Jefferies Financial Group started coverage on Revolution Medicines in a report on Monday, March 16th. They set a “buy” rating on the stock. Five analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $78.94.

Revolution Medicines Stock Up 1.4%

RVMD stock opened at $98.64 on Thursday. The company has a market cap of $19.55 billion, a P/E ratio of -16.69 and a beta of 0.99. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $124.49. The company’s 50-day moving average price is $99.06 and its 200 day moving average price is $80.05. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same quarter in the prior year, the firm earned ($1.12) EPS. On average, research analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Mark A. Goldsmith sold 12,871 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $1,280,407.08. Following the completion of the transaction, the insider directly owned 276,698 shares of the company’s stock, valued at $27,525,917.04. This trade represents a 4.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Jack Anders sold 2,753 shares of Revolution Medicines stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $273,868.44. Following the transaction, the chief financial officer directly owned 125,512 shares of the company’s stock, valued at approximately $12,485,933.76. This represents a 2.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 149,592 shares of company stock worth $15,010,732. 8.20% of the stock is owned by insiders.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.